Citations

Mayo Clinic

Showing 10 of 108572 citations.

Lewy body dementia: Overcoming barriers and identifying solutions
Agarwal, Kanishka, Backler, Wendi, Bloom, Leah, Cha, Jang‐Ho , Denslow, Maria, Ferman, Tanis J. , Gomperts, Stephen N. , Irizarry, Michael C. , Kantarci, Kejal , Kaushik, Harsh, Kietlinski, Matt, Koenig, Aaron, Leverenz, James B., McLean, Pamela J. , Montine, Thomas J. , Moose, Sandra O., Panier, Valery, Ringel, Michael S. , Scholz, Sonja W. , Small, J C, Ward, Rebecca , Witten, L.M., Ward, Rebecca A , Scholz, Sonja W , Kantarci, Kejal , Ferman, Tanis J , McLean, Pamela J , Bayram, Ece , Boeve, Bradley F. , Galasko, Douglas , Galvin, James E. , Leverenz, James B. , McKeith, Ian G. , O'Brien, John Tiernan , Ramanathan, Sharad , Small, Jonnell, Sperling, Reisa Anne , Taylor, Angela E. , Taylor, John‐Paul , Hyman, Bradley T.

Alzheimer's & Dementia | January 24, 2024 | Volume: 20 | Issue: 3 | Pages: 2298-2308

10.1002/alz.13674 | PMID 38265159 Get It

AbstractDespite its high prevalence among dementias, Lewy body dementia (LBD) remains poorly understood with a limited, albeit growing, evidence base. The public‐health burden that LBD imposes is worsened by overlapping pathologies, which contribute to misdiagnosis, and lack of treatments. For this report, we gathered and analyzed public‐domain information on advocacy, funding, research outputs, and the therapeutic pipeline to identify gaps in each of these key elements. To further understand the current gaps, we also conducted interviews with leading experts in regulatory/governmental agencies, LBD advocacy, academic research, and biopharmaceutical research, as well as with funding sources. We identified wide gaps across the entire landscape, the most critical being in research. Many of the experts participated in a workshop to discuss the prioritization of research areas with a view to accelerating therapeutic development and improving patient care. This white paper outlines the opportunities for bridging the major LBD gaps and creates the framework for collaboration in that endeavor.Highlights A group representing academia, government, industry, and consulting expertise was convened to discuss current progress in Dementia with Lewy Body care and research. Consideration of expert opinion,natural language processing of the literature as well as publicly available data bases, and Delphi inspired discussion led to a proposed consensus document of priorities for the field.
The Neutrophil/Lymphocyte Ratio and Outcomes in Hospitalized Patients with Community-Acquired Pneumonia: A Retrospective Cohort Study
Tekin, Aysun , Wireko, F.W. , Odeyemi, Yewande , Wireko, Felix W., Odeyemi, Yewande E, Tekin, Aysun , Gajic, Ognjen

Biomedicines | January 24, 2024 | Volume: 12 | Issue: 2 | Pages: 260

10.3390/biomedicines12020260 | PMID 38397862 Get It

We aimed to assess the prognostic role of the neutrophil/lymphocyte ratio (NLR) in community-acquired pneumonia (CAP) via a single-center retrospective cohort of hospitalized adult patients from 1/2009 to 12/2019. Patients were dichotomized into lower NLR (≤12) and higher NLR (>12). The primary outcome was mortality. ICU admission and hospital- and ICU-free days were secondary outcomes. The pneumonia severity index (PSI) and the NLR’s ability to predict outcomes was also tested. An NLR ≤12 was observed in 2513 (62.2%) patients and >12 in 1526 (37.8%). After adjusting for PSI, the NLR was not associated with hospital mortality (odds ratio [OR] 1.115; 95% confidence interval [CI] 0.774, 1.606; p = 0.559), but it was associated with a higher risk of ICU admission (OR 1.405; 95% CI 1.216, 1.624; p < 0.001). The PSI demonstrated acceptable discrimination for mortality (area under the receiver operating characteristic curve [AUC] 0.78; 95% CI 0.75, 0.82) which was not improved by adding the NLR (AUC 0.78; 95% CI 0.75, 0.82, p = 0.4476). The PSI’s performance in predicting ICU admission was also acceptable (AUC 0.75; 95% CI 0.74, 0.77) and improved by including the NLR (AUC 0.76, 95% CI 0.74, 0.77, p = 0.008), although with limited clinical significance. The NLR was not superior to the PSI for predicting mortality in hospitalized CAP patients.
Submucosal Epstein-Barr Virus Positive Polymorphic B-cell Lymphoproliferative Disorder of the Larynx: A Case Report
Mumtaz, Sehreen , Candelo, Estephanía , Krishna, Murli , Jiang, Liuyan , Bhatt, Alok A. , Bridges, Margaret, Cardona-Cardona, Andrés Felipe , Rutt, Amy L. , Berianu, Florentina , Butendieck, Ronald R., Cardona, Andres , Rutt, Amy L. , Gomez, Estephania Candelo , Bhatt, Alok A , Mumtaz, Sehreen , Bridges, Margaret

Ear, Nose & Throat Journal | January 24, 2024 | Volume: 105 | Issue: 8 | Pages: No page available

10.1177/01455613231226017 | PMID 38264837 Get It

Epstein-Barr virus (EBV) belongs to the group of human herpes virus and can cause clinical and subclinical infections. Although EBV-related disease presentations are similar, they can lead to oncogenic transformation with various clinical manifestations. A thorough workup with morphology, immunohistochemistry, and molecular studies is crucial for the diagnosis of EBV-positive polymorphic B-cell lymphoproliferative disorder, not otherwise specified (NOS), which is a new entity introduced by International Consensus Classification in 2022. We describe an interesting presentation of EBV-positive polymorphic B-cell lymphoproliferative disorder with laryngeal involvement to bring awareness to this entity and we would like to address the need for more accessible treatment options.
In silico modelling of the effect of pyloric intervention procedures on gastric flow and emptying in a stomach with gastroparesis
Kuhar, Sharun , Seo, Jung-Hee , Pasricha, Pankaj J. , Mittal, Rajat

Journal of The Royal Society Interface | January 24, 2024 | Volume: 21 | Issue: 210 | Pages: No page available

10.1098/rsif.2023.0567 | PMID 38263890 Get It

Pyloric interventions are surgical procedures employed to increase the gastric emptying rate in gastroparesis patients. In this study, we use an in silico model to investigate the consequences of pyloric intervention on gastric flow and emptying for two phenotypes of gastroparesis: antral hypomotility and decreased gastric tone. The transpyloric pressure gradient predicted by the in silico model, based on viscous fluid flow equations, is compared against in vivo measurements. Both phenotypes exhibit a similar pre-procedural emptying rate reduction, but after pyloric surgery, antral hypomotility case with preserved gastric tone shows significant improvements in emptying rates, up to 131%, accompanied by bile reflux from the duodenum into the stomach. Conversely, severely reduced gastric tone cases exhibited a post-procedural reduction in the net emptying rate due to the relatively larger bile reflux. In cases with a combination of antral hypomotility and reduced gastric tone, post-procedural improvements were observed only when both conditions were mild. Our findings highlight the pivotal role of the relative increase in pyloric orifice diameter in determining post-operative emptying rates. The study suggests a possible explanation for the selective response of patients toward these procedures and underscores the potential of in silico modelling to generate valuable insights to inform gastric surgery.
Pressure Overload is Associated with Right Ventricular Dyssynchrony in Heart Failure with Reduced Ejection Fraction
Monzo, Luca , Tupý, Marek, Reichenbach, Adrian, Jurčová, Ivana , Beneš, Jan , Mlatečková, Lenka, Terš, Jiří, Kautzner, Josef , Borlaug, Barry A. , Melenovský, Vojtěch

ESC Heart Failure | January 24, 2024 | Volume: 11 | Issue: 2 | Pages: 1097-1109

10.1002/ehf2.14682 | PMID 38263857 Get It

Abstract Aims The determinants and relevance of right ventricular (RV) mechanical dyssynchrony in heart failure with reduced ejection fraction (HFrEF) are poorly understood. We hypothesized that increased afterload may adversely affect the synchrony of RV contraction. Methods and results A total of 148 patients with HFrEF and 36 controls underwent echocardiography, right heart catheterization, and gated single-photon emission computed tomography to measure RV chamber volumes and mechanical dyssynchrony (phase standard deviation of systolic displacement timing). Exams were repeated after preload (N = 135) and afterload (N = 15) modulation. Patients with HFrEF showed higher RV dyssynchrony compared with controls (40.6 ± 17.5° vs. 27.8 ± 9.1°, P &lt; 0.001). The magnitude of RV dyssynchrony in HFrEF correlated with larger RV and left ventricular (LV) volumes, lower RV ejection fraction (RVEF) and LV ejection fraction, reduced intrinsic contractility, increased heart rate, higher pulmonary artery (PA) load, and impaired RV–PA coupling (all P ≤ 0.01). Low RVEF was the strongest predictor of RV dyssynchrony. Left bundle branch block (BBB) was associated with greater RV dyssynchrony than right BBB, regardless of QRS duration. RV afterload reduction by sildenafil improved RV dyssynchrony (P = 0.004), whereas preload change with passive leg raise had modest effect. Patients in the highest tertiles of RV dyssynchrony had an increased risk of adverse clinical events compared with those in the lower tertile [T2/T3 vs. T1: hazard ratio 1.98 (95% confidence interval 1.20–3.24), P = 0.007]. Conclusions RV dyssynchrony is associated with RV remodelling, dysfunction, adverse haemodynamics, and greater risk for adverse clinical events. RV dyssynchrony is mitigated by acute RV afterload reduction and could be a potential therapeutic target to improve RV performance in HFrEF.
A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease
Simadibrata, Daniel Martin , Lesmana, Elvira , Fass, Ronnie

Journal of Gastroenterology and Hepatology | January 24, 2024 | Volume: 39 | Issue: 5 | Pages: 796-805

10.1111/jgh.16475 | PMID 38263507 Get It

AbstractBackground and AimUp to 40% of gastroesophageal reflux disease (GERD) patients experience inadequate symptom relief with a proton pump inhibitor (PPI), termed PPI‐resistant or refractory GERD. Vonoprazan, a potassium‐competitive acid blocker, has better efficacy than PPI in suppressing gastric acid secretion. This meta‐analysis summarizes the efficacy and safety of vonoprazan for treating PPI‐resistant GERD (both erosive esophagitis [EE] and non‐erosive reflux disease [NERD]).MethodsFour electronic databases (Medline, Embase, SCOPUS, and CENTRAL) were searched for studies indexed until August 1, 2023. Both observational studies and clinical trials assessing the efficacy and safety of vonoprazan in PPI‐resistant GERD were included. Efficacy outcomes included healing and maintenance rates of EE and improvement of the Frequency Scale for Symptoms of GERD (FSSG) scores. Serious adverse events (SAEs) were considered a safety outcome. The modified Newcastle‐Ottawa Scale (NOS) was used to assess study quality.ResultsTwelve studies were included in this meta‐analysis. Healing rates of PPI‐resistant EE with vonoprazan 20 mg were 91.7% (95% CI 86.8–94.8%) and 88.5% (95% CI 69.7–96.2%) at weeks 4 and 8, respectively. For healed PPI‐resistant EE, the overall maintenance rates with vonoprazan 10 mg were 82.6% (95% 61.2–95.0%) at week 8, 86.0% (95% CI 72.1–94.7%) at week 24, and 93.8% (95% CI 69.8–99.8%) at week 48. FSSG scores were improved in 74.6% (95% CI 65.8–81.7%) and 51.9% (95% CI 37.8–65.7%) of patients at weeks 4 and 8. Overall, no SAE was reported.ConclusionVonoprazan demonstrated high efficacy in the healing and maintenance of PPI‐resistant EE and moderate efficacy for the improvement of FSSG score. Vonoprazan was well tolerated in PPI‐resistant GERD patients.
A ghost in the machine: is machine learning necessary for prediction of choledocholithiasis?
Law, Ryan , Pérez‐Miranda, Manuel , Perez-Miranda, Manuel , Law, Ryan

Endoscopy | January 23, 2024 | Volume: 56 | Issue: 03 | Pages: 172-173

10.1055/a-2233-0136 | PMID 38262425 Get It

Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
Orme, Jacob J. , Ravi, Praful , Childs, Daniel S , Orme, Jacob J , Ravi, Praful , Childs, Daniel S.

Journal of Clinical Oncology | January 23, 2024 | Volume: 42 | Issue: 10 | Pages: 1095-1097

10.1200/jco.23.02410 | PMID 38261976 Get It

Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102
Saber, Wael , Bansal, Aasthaa , Li, Li , Scott, Bart L. , Sangaralingham, Lindsey R. , Thao, Viengneesee , Roth, Joshua A. , Wright, Winona , Pidala, Joseph A. , Mishra, Asmita , Westervelt, Peter, Nakamura, Ryotaro , Ramsey, Scott D. , Li, Lily , Mishra, Asmita , Maziarz, Richard Thomas , McGuirk, Joseph , Cutler, Corey S. , Ramsey, Scott , Steuten, Lotte , McGuirk, Joseph P.

JCO Oncology Practice | January 23, 2024 | Volume: 20 | Issue: 4 | Pages: 572-580

10.1200/op.23.00413 | PMID 38261970 Get It

PURPOSE BMT CTN 1102 was a phase III trial comparing reduced-intensity allogeneic hematopoietic cell transplantation (RIC alloHCT) to standard of care for persons with intermediate- or high-risk myelodysplastic syndrome (MDS). We report results of a cost-effectiveness analysis conducted alongside the clinical trial. METHODS Three hundred eighty-four patients received HCT (n = 260) or standard of care (n = 124) according to availability of a human leukocyte antigen–matched donor. Cost-effectiveness was calculated from US commercial and Medicare perspectives over a 20-year time horizon. Health care utilization and costs were estimated using propensity score–matched cohorts of HCT recipients in the OptumLabs Data Warehouse (age 50-64 years) and Medicare (age 65 years and older). EuroQol 5 Dimension (EQ-5D) surveys of trial participants were used to derive health state utilities. RESULTS Extrapolated 20-year overall survival for those age 50-64 years was 29% for HCT (n = 105) versus 13% for usual care (n = 44) and 31% for HCT (n = 155) versus 12% for non-HCT (n = 80) for those age 65 years and older. HCT was more effective (+2.36 quality-adjusted life-years [QALYs] for age 50-64 years and +2.92 QALYs for age 65 years and older) and more costly (+$452,242 in US dollars (USD) for age 50-64 years and +$233,214 USD for age 65 years and older) than usual care, with incremental cost-effectiveness ratios of $191,487 (USD)/QALY and $79,834 (USD)/QALY, respectively. For persons age 50-64 years, there was a 29% chance that HCT was cost-effective using a willingness-to-pay (WTP) threshold of $150K (USD)/QALY and 51% at a $200K (USD)/QALY. For persons age 65 years and older, the probability was 100% at a WTP >$150K (USD)/QALY. CONCLUSION Among patients age 65 years and older with high-risk MDS, RIC HCT is a high-value strategy. For those age 50-64 years, HCT is a lower-value strategy but has similar cost-effectiveness to other therapies commonly used in oncology.
Implementing a Metabolism-Informed Approach for Smoking Cessation in an Alaska Tribal Health System: Study Protocol for a Single-Arm Implementation Pilot Trial
Jansen, Kelley , Tranby, Brianna , Shane, Aliassa L. , Takeno, Todd, Chadwick, Kelly , Shaw, Jennifer L. , Sinicrope, Pamela

No container title available | January 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3874126/v1 | PMID 38343834 Get It

Abstract Background Individualized treatment for commercial tobacco smoking cessation, such as through the utilization of the nicotine metabolite ratio (NMR), offers substantial clinical benefit. NMR is a metabolism-informed biomarker that can be used to guide medication selection. NMR testing is particularly promising for tobacco cessation efforts in populations with high rates of smoking, such as some Alaska Native and American Indian (AN/AI) communities. To date, no prior study has evaluated the implementation of NMR-guided tobacco cessation with AN/AI populations. Methods The present “QUIT” protocol is a two-phase study that will occur at Southcentral Foundation (SCF), an Alaska Native-owned health system, serving 70,000 AN/AI people, based in Anchorage, Alaska. In Phase one, qualitative interviews with customer-owners (patients), providers and administrators (n = 36) and a 10-participant beta-test will be used to refine a strategy to implement NMR testing in the health system. Phase two will involve a single-arm pilot trial (n = 50) and qualitative interviews throughout data collection (n = 48) to evaluate the implementation strategy and explore the real-world acceptability and feasibility of NMR testing to guide tobacco cessation with AN/AI populations. Discussion This study utilizes a community-based participatory approach to refine and implement a nicotine metabolism-informed smoking cessation program in a Tribal healthcare setting. The process and findings from this study will reflect the importance of customer-owner choice and honor the lived experience involved in quitting commercial tobacco. Pilot study data will inform the effect and sample sizes required for a future pragmatic trial of NMR-guided smoking cessation.